Evaluación del impacto de la sintomatología urinaria en la calidad de vida de los pacientes con síndrome de vejiga dolorosa/dolor pélvico crónico y cistitis rádica: estudio EURCIS

ObjectivesTo evaluate the impact of urinary symptoms of Painful Bladder/Pelvic Pain Syndrome and Radiation Cystitis (PBCPPS) on the Quality of Life, and self-esteem of the patient.Material and methodsAn observational, multicenter, epidemiological and cross-sectional study was performed on patients with Painful Bladder/Chronic Pelvic Pain Syndrome and Radiation Cystitis. Data was recorded on severity of urinary symptoms and QoL impairment using the PUF Score. The patients evaluated the QoL deterioration grade through the King's Health Questionnaire (KHQ), and the level of their anxiety and self-esteem with the Goldberg's Anxiety Scale (GAS) and Rosenberg's Self-Esteem Scale (RSES), respectively. Post-hoc comparisons were performed between the results of the KHQ of this study and a sample of patients with urinary incontinence (UI). Results on RSES were analyzed with data from the general population and from patients with erectile dysfunction.ResultsA total of 530 cases, mostly female patients, who had been diagnosed with PBCPPS, were analyzed. High levels of deterioration in QoL were described: KHQ scores were significantly higher when compared with patients with UI (P < .01). Involvement of self-esteem was higher in patients with RC and men, who obtained scores similar to those of patients with erectile dysfunction.ConclusionsPatients with Painful Bladder Syndrome/Chronic Pelvic Pain Syndrome and Radiation Cystitis present high levels of anxiety, and significant reductions in both quality of life and self-esteem. Especially for men, this affectation is similar to that caused by erectile dysfunction.     

Gastrointestinal radiation injury:Symptoms,risk factors and mechanisms

Ionising radiation therapy is a common treatment modality for different types of cancer and its use is expected to increase with advances in screening and early detection of cancer.Radiation injury to the gastrointestinal tract is important factor working against better utility of this important therapeutic modality.Cancer survivors can suffer a wide variety of acute and chronic symptoms following radiotherapy,which significantly reduces their quality of life as well as adding an extra burden to the cost of health care.The accurate diagnosis and treatment of intestinal radiation injury often represents a clinical challenge to practicing physicians in both gastroenterology and oncology.Despite the growing recognition of the problem and some advances in understanding the cellular and molecular mechanisms of radiation injury,relatively little is known about the pathophysiology of gastrointestinal radiation injury or any possible susceptibility factors that could aggravate its severity.The aims of this review are to examine the various clinical manifestations of post-radiation gastrointestinal symptoms,to discuss possible patient and treatment factors implicated in normal gastrointestinal tissue radiosensitivity and to outline different mechanisms of intestinal tissue injury.     

碘 131 治疗期间辐射防护方法的研究进展

〔摘 要〕 同位素治疗手段及医学显像技术在医疗科技中发挥着越来越重要的作用，在这一趋势之下，放射性治疗 药物在临床中效果更加明显，同时其应用也变得越来越广泛。但同时还需要意识到，放射性治疗药物的应用，本质上 对于患者及医护工作人员都会产生一定的影响，也就是辐射影响。碘 131 主要在一些甲状腺疾病的治疗中进行应用， 其具备明显的靶向性治疗优势和价值，并且碘 131 还可以用于标记多种化合物，在临床中的肝、胆、肾等器官疾病的 诊断过程中均有运用，为了碘 131 在治疗中的价值和作用得到全面发挥，就需要注重辐射防护方法的应用。本研究针 对碘 131 治疗期间辐射防护方法的研究进展进行了系统研究和分析，目的在于提升碘 131 治疗效果和辐射防护效果。     

2008-2017年广东省职业性放射性疾病诊断情况分析

目的 了解广东省职业性放射性疾病的诊断情况，分析职业接触特点和职业接触关键控制点。方法 对2008-2017年广东省内申请职业性放射性疾病的35个病例进行分析。结果 诊断为职业性放射性疾病的有10例，其中职业性放射性肿瘤8例，诊断时年龄M（P0~P100）为62.5（42~76）岁，放射工龄M（P0~P100）为27.5（5~33）年，病因概率PC值在26.34%~97.98%之间，PC值95%可信限上限均大于50%，75%的病例为井下矿石与矿物处理工作者，职业中同时接触α、β、γ射线。急性放射性皮肤损伤2例，职业中接触X、β射线，2人均为意外受照，且无法估算出两人确切的受照剂量。结论 部分用人单位和放射工作人员的知识、技术水平、防护意识还有待进一步提高，建议加强辐射防护培训，尤其是上岗前培训。     

CHEMO- AND RADIOSENSITIVITY TESTING IN A PATIENT WITH ATAXIA TELANGIECTASIA AND HODGKIN DISEASE

Treatment of Hodgkin disease (HD) in ataxia telangiectasia (AT) patients is hampered by hypersensitivity to radiation and chemotherapy. Most patients die, due to toxicity or, rarely, to progressive disease. The authors report on a 9-year-old girl with stage IIA HD and AT. She was treated with a tailored combined modality approach. No unacceptable toxicity was found, but the girl died of a relapse outside their radiation field. In comparison with fibroblasts of non-AT patients, the fibroblasts of the patient were 3 times as sensitive for radiotherapy but just 1.2 times as sensitive for doxorubicin. A good correlation was shown between in vitro radio- and chemosensitivity testing and the observed clinical toxicity. The authors suggest, therefore, treating AT patients as much as possible according to standard protocols by adjusting the radiotherapy delivery and the chemotherapy regimen to individual doses derived from in vitro radio- and chemosensitivity testing.